The Tools Exist. The Question Is Whether We’ll Use Them.
Next-Generation Cervical Screening: HPV Testing, AI-Enhanced Triage, and Point-of-Care Innovations
Cervical cancer prevention is no longer limited by what we can detect. It is limited by whether detection leads to action.
Across the care continuum of screening, triage, treatment, and follow-up, breakdowns persist that prevent proven tools from functioning as a cohesive system.
Every April 7, World Health Day asks us to take stock. The numbers are clear, more than 350,000 women will die of cervical cancer this year. More than 90% of them will be in low- and middle-income countries. And nearly all of those deaths were preventable.
This is not a scientific failure. We have effective vaccines, Human Papillomavirus (HPV) testing that detects cancer risk years before disease develops, AI-assisted triage tools, and point-of-care diagnostics capable of delivering results and treatment in a single visit. The science is not what’s failing these women. Our systems are. The challenge now is ensuring these tools function together as part of a complete, connected pathway of care.
New tools matter only if they reach the people who need them most. The question is never just what works, but for whom, and under what conditions.
HPV Testing: The Gap Is Not Scientific
Primary HPV testing detects high-risk viral strains years before precancerous changes develop, significantly outperforming traditional cytology. In the U.S., validated self-collection options now allow home-based sample collection, a meaningful step toward reducing access barriers.
But in low- and middle-income countries (LMICs), programs have been solving harder problems with fewer resources, and the results are instructive. In India, community health workers have used self-sampling kits to reach women in rural communities who would otherwise never be screened. In Kenya, mobile clinics pairing HPV testing with same-visit treatment have reduced advanced-stage diagnoses in underserved populations. These programs work because implementation was designed around real barriers: geography, workforce constraints, and the reality that a woman who must return for results often doesn’t. These programs did not succeed because the technology was new. They succeeded because the system was designed to ensure a positive test led directly to action.
AI-Enhanced Triage: A Tool, Not a Solution
A positive HPV test is a signal, not a diagnosis. AI-assisted analysis of colposcopy and visual inspection with acetic acid (VIA) images is showing genuine promise, improving specificity, reducing unnecessary procedures, and helping direct limited specialist time toward higher-risk cases in both National Health Service (NHS) settings and under-resourced township clinics in South Africa.
But we should be clear-eyed: AI extends clinical judgment; it does not replace it. And its value depends entirely on whether the surrounding system, referral pathways, treatment access, follow-up infrastructure, actually functions. An algorithm that flags a precancerous lesion in a clinic with no treatment capacity has not saved anyone. When systems are fragmented, adding intelligence to one step does not fix the gaps between steps. Implementation is the intervention.
Point-of-Care Diagnostics: The Follow-Up Gap Is Costing Lives
Loss to follow-up may be the most consequential and least discussed failure point in cervical cancer prevention. When screening and results are separated across visits, a significant share of women never receive results or access treatment. That is a systems failure, not a patient failure.
Point-of-care (POC) HPV diagnostics address this directly. In Rwanda, solar-powered diagnostic hubs have enabled same-visit testing and treatment in communities without reliable laboratory access. In Canada, POC platforms in Indigenous communities have driven high treatment completion rates by eliminating return visits. The pattern is consistent: when screening and action happen in the same encounter, outcomes improve. This is the difference between access and completion. If same-visit models consistently improve outcomes, the question is no longer whether they work. It is why they are not yet standard wherever they are feasible.
What World Health Day Should Ask of Us
The barriers that remain, cost, workforce training, supply continuity, are real. But they are not arguments against action. They are the specifications for what implementation science needs to solve.
STO’s charge is to close the distance between what is scientifically possible and what is actually delivered, especially for the women most likely to be left behind. HPV testing, AI triage, and point-of-care diagnostics are not the finish line. They are the means.
So here is the question April 7 should leave us with: What is the one barrier in your clinic, your program, your health system, standing between a woman and a completed screening encounter? Name it. Then work to remove it.
That is how cervical cancer gets eliminated. Not by waiting for better tools, but by building better systems around the ones we already have and ensuring that every step connects.
